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Structural variations in the chromosome 22q11.2 region medi-
ated by nonallelic homologous recombination result in 22q11.2
deletion (del22q11.2) and 22q11.2 duplication (dup22q11.2)
syndromes. The majority of del22q11.2 cases have facial and
cardiacmalformations, immunologic impairments, specific cog-
nitive profile and increased risk for schizophrenia and autism
spectrum disorders (ASDs). The phenotype of dup22q11.2 is
frequently without physical features but includes the spectrum
of neurocognitive abnormalities. Although there is substantial
evidence that haploinsufficiency for TBX1 plays a role in the
physical features of del22q11.2, it is not known which gene(s) in
the critical 1.5Mb region are responsible for the observed
spectrum of behavioral phenotypes. We identified an individual
with a balanced translocation 46,XY,t(1;22)(p36.1;q11.2) and a
behavioral phenotype characterized by cognitive impairment,
autism, and schizophrenia in the absence of congenital malfor-
mations. Using somatic cell hybrids and comparative genomic
hybridization (CGH) we mapped the chromosome-22 break-
point within intron 7 of the GNB1L gene. Copy number evalua-
tions and directDNA sequencing ofGNB1L in 271 schizophrenia
and 513 autism cases revealed dup22q11.2 in two families with
autism and private GNB1L missense variants in conserved res-
idues in three families (P¼ 0.036). The identified missense
variants affect residues in the WD40 repeat domains and are
predicted to have deleterious effects on the protein. Prior studies
provided evidence thatGNB1Lmay have a role in schizophrenia.
Our findings support involvement of GNB1L in ASDs as well.
 2011 Wiley Periodicals, Inc.
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INTRODUCTION
The chromosome 22q11.2 genomic region harbors four low-
copy repeats that make it susceptible to nonallelic homologous
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recombination that is responsible for the 22q11 deletion
(del22q11.2) and duplication (dup22q11.2) syndromes
[Stankiewicz and Lupski 2002]. Del22q11.2 is the most common
genomic disorder, with a frequency of 1 in 4,000 to 1 in 7,000 births
[Botto et al., 2003;Oskarsdottir et al., 2004]. This complex disorder
has been called velocardiofacial syndrome (VCFS) [MIM 192430]
for its associated facial dysmorphism, palatal clefting or insuffi-
ciency, and conotruncal heart abnormalities, orDiGeorge sequence
(DGS) [MIM 188400] when the immune system and parathyroid
function are compromised. Del22q11.2 also has a prominent
cognitive and behavioral component [Murphy 2005]. Individuals
with del22q11.2 have a lower IQ than expected and a complex
psychoeducational profile characterized by language impairment
and higher verbal than performance IQ [Moss et al., 1999; Antshel
et al., 2008]. Del22q11.2 greatly increases the risk for psychiatric
disorders. An autism spectrum disorder (ASD) is diagnosed in as
many as 50% and schizophrenia or related psychosis develops in
approximately one-third of individuals with del22q11.2 [Murphy
et al., 1999; Fine et al., 2005; Vorstman et al., 2006; Antshel et al.,
2007; Niklasson et al., 2009]. Conversely, the microdeletion has
been found in approximately 1–3% of adults with schizophrenia
and with much higher frequencies in the subsets with childhood
onset, making del22q11.2 the most frequent genetic cause of
schizophrenia in the general population [Yan et al., 1998;Wiehahn
et al., 2004; Horowitz et al., 2005]. Complex neurodevelopmental
phenotypes also characterize the newly recognized reciprocal
dup22q11.2 syndrome [MIM 608363]. The phenotype of the
individuals with dup22q11.2 is exceedingly diverse—some indi-
viduals have no apparent abnormalities, but others manifest phe-
notypes ranging from congenital malformations reminiscent of
del22q11.2 to behavioral disorders including intellectual disability,
ASD, and learning disorders [Mukaddes and Herguner, 2007;
Ramelli et al., 2008; Lo-Castro et al., 2009], further supporting
the importance of the 22q11.2 region in cognition and behavior.
Most VCFS/DGS cases have a deletion spanning 3Mb or, less
frequently, a nested deletion of 1.5Mb, mediated by homologous
recombination between different blocks of low-copy repeats. As the
range of clinical features in groups with different size deletions is
indistinguishable, the boundaries of the 1.5Mb deletion define a
critical del22q11.2 region (NCBI36/hg18 17.2-18.7Mb) that con-
tains 31 genes [Funke et al., 1999]. Rare patients with unique
deletions, translocations or mutations in the region offer an
opportunity to dissect the genotypic and phenotypic components
of the syndrome. Studies of such patients and of mouse models
provide strong evidence that mutations in one of these genes,
T-Box1 (TBX1 [MIM 602054]), can cause the structural craniofa-
cial, cardiovascular, thymic and pharyngeal anomalies, but evi-
dence for the role of TBX1 in the psychiatric/behavioral problems is
conflicting [Gong et al., 2000; Yagi et al., 2003; Liao et al., 2004;
Torres-Juan et al., 2007; Zweier et al., 2007].
Other genes in the critical del22q11.2 region have also been
considered as candidates for the neurobehavioral phenotypes,
based on their functions, expression patterns in humans and
presence of behavioral abnormalities in mouse models [Gogos
et al., 1998; Gothelf et al., 2005; Paterlini et al., 2005]. Recently,
significant evidence for association between schizophrenia
and Guanine Nucleotide-Binding Protein, Beta-1-Like (GNB1L
[MIM 610778]) was reported in a case-control association study
[Williams et al., 2008]. This observation, combined with the
findings of reduced expression of GNB1L in postmortem brains
of schizophrenics [Ishiguro et al., 2010] and the effect of heterozy-
gous deletion of Gnbl1 on prepulse inhibition, a schizophrenia
endophenotype, in amousemodel [Paylor et al., 2006], suggest that
GNB1L is associated with the schizophrenia phenotype observed in
del22q11.2. Herein we report an individual with a history of autism
and schizophrenia who was found to have a balanced translocation
involving the 22q11.2 region. We mapped the chromosome
22 breakpoint to the GNB1L gene. We also detected additional
rare and possibly damaging GNB1L sequence variants in subjects




The proband and his family members provided informed consent
and blood samples under a protocol approved by the University of
Washington Institutional Review Board.
ASD Cases
Cases were identified from families with two ormore children with
ASD. The ASD cohort is comprised of 513 unrelated individuals,
most of whom have participated in our previous genetic studies
[Schellenberg et al., 2006; Chapman et al., 2011; Korvatska et al.,
2011]. More than 80% of cases are self-identified as White,
approximately 10% are of mixed race, and less than 10% are US
minorities. The University of Washington and University of
Pittsburgh Institutional Review Boards approved the relevant
study, and informed consent was obtained from all participants
and/or their parents. Children with a reported ASD were assessed
using the Autism Diagnostic Interview-Revised (ADI-R) [Lord
et al., 1994] and Autism Diagnostic Observation Schedule-Generic
(ADOS-G) [Lord et al., 2000] by trained clinicians, and assigned a
DSM-IV [APA, 1994] diagnosis. Individuals designated as affected
met DSM-IV criteria for an ASD based on ADI-R, ADOS-G, and
expert clinical judgment.
Schizophrenia Cases
The 271 cases were participants in either the 7-site Consortium on
the Genetics of Schizophrenia (COGS) or the Veterans Affairs
Cooperative Studies Program # 166, Genetic Linkage of Schizo-
phrenia study, and provided informed consent under protocols
approved by the Institutional Review Boards at the relevant sites.
One hundred fifty five cases were European-Americans and 116
wereAfrican-American. For the current project, all casesmetDSM-
IV criteria for schizophrenia using the Diagnostic Interview for
Genetic Studies and related instruments, as described in previous
publications [Tsuang et al., 2000; Calkins et al., 2007].
Control Subjects
Unrelated participants in other studieswhohad provided informed
consent for sharing DNA or genetic information for use in research
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of other genetic disorders served as controls. These individuals
were not screened for autism or schizophrenia. Control subjects
were self-identified as European-American (n¼ 630) or African-
American (n¼ 414).
Cytogenetic Evaluations
The initial karyotype of the proband with a translocation was
analyzed at an outside clinical laboratory. Karyotype and fluore-
scence in situ hybridization (FISH) analyses of his relatives were
performed in the clinical cytogenetics laboratory of the University
of Washington.
Somatic Cell Hybrid Construction
Somatic cell hybrids were constructed using Conversion Technol-
ogy at the Mayo Clinic Cytogenetics Laboratory [Highsmith et al.,
2007]. An EBV transformed lymphoblastoid cell line from the
proband was electrofused with E2 cells and 215 mouse/human
hybrid colonies were obtained. Twenty-one colonies were expand-
ed and evaluated by FISH for the presence of chromosomes 1 and22
withwhole chromosome paint probes. Separate somatic cell hybrid
lines that retained only the derivative chromosome 22 (der22) or
the derivative chromosome 1 (der1) and not their normal counter-
parts were isolated and expanded for DNA extraction.
Fine Mapping of the Translocation Breakpoints
Comparative genomic hybridization (CGH). DNAs from the
separate hybrid cell lines containing either der22 or der1 were sent
to NimbleGen Systems (Madison, WI) where they were differen-
tially labeledwith either Cy3-dCTPorCy5-dCTP andhybridized to
chromosome-specific oligonucleotide arrays (NimbleGen HG18
Chr1 and HG18 Chr22 designs) according to manufacturer’s
protocols. Each NimbleGen chromosome specific array contains
385,000 probes. The median probe spacing is 531 base pairs for
chromosome 1 and 65 base pairs for chromosome 22. The hybrid-
izations localized the breakpoints at sufficiently high resolution to
enable PCR based breakpoint cloning.
Capillary sequencing. PCRprimers for regions that flanked the
breakpoints were designed and tested on normal chromosomes
1 and 22 (Table S I, supplemental material). To establish the exact
base-pair positions of the chromosomal breaks on the derivative
chromosomes, PCRwas thenperformedusing primers thatworked
during the control runs. For this purpose, the forward primers of
chromosome 1 were combined with the forward primers of chro-
mosome22 to span the breakpoint onder22 and the reverse primers
of chromosome 1 were combined with the reverse primers of
chromosome 22 to span the breakpoint on the der1. The PCR
products were sequenced on an ABI 3130XL DNA analyzer. The
PCR and sequencing conditions were the same as described in
‘‘Mutation screening’’ section.
Detection of Copy Number Variation in GNB1L
by TaqMan Copy Number Assay
To detect deletions/duplications of GNB1L, we conducted
TaqMan based real-time quantitative copy number tests accord-
ing to the manufacturer’s protocol (Applied Biosystems, Carlsbad,
CA). The TaqMan copy number assay is a duplex reaction with a
FAM-assay targeting the gene of interest and a VIC-assay
targeting the reference gene (Table S II, supplementary material).
The copy number is determined by relative quantification using a
reference sample known to have two copies of the gene of interest.
Each DNA sample was analyzed in triplicate on an Applied Bio-
systems 7500 Real-Time PCR System. For assay quality, positive
control DNA from an individual with del22q11.2 was obtained
from the Coriell cell repository (Coriell GM07939). Calculation of
gene copy number for each sample was done using the Copy Caller
Software V1.0 (Applied Biosystems).
Confirmation of GNB1L Duplication by CGH
Array-CGH experiments were performed as described previously
(73), with somemodification. Briefly, 250 ng of each of patient and
sex matched reference DNA was denatured at 98C with Cy3- or
Cy5-labeled random monomer (TriLink Biotechnologies, San
Diego, CA) in 62.5mM Tris-HCl, pH 7.5, 6.25mM MgCl2, and
0.0875% b-mercaptoethanol. The denatured sample was chilled on
ice, and then incubated with 100 units (exo-) Klenow fragment
(NEB, Ipswich, MA) and dNTP mix (6mM each; Invitrogen,
Carlsbad, CA) in Tris, EDTA buffer, for 2 hr at 37C. Reactions
were terminated by addition of 0.5M EDTA (pH 8.0); the end
products were precipitated with isopropanol and resuspended in
water. The Cy-labeled test sample and reference samples were then
combined (10 mg each) and hybridized to a custom-designed
(Girirajan and Eichler unpublished) 400 K oligonucleotide array
(Agilent Technologies, Santa Clara, CA) at 60C for 40 hr. The
arrays were washed in commercially available solutions and
scanned. The resulting TIFF images were analyzed with Feature
Extraction software and output from this software was imported
into CGH Analytics software for final analysis. The data were
analyzedwith theGenomicWorkbench using anADM-2 algorithm
with a 0.25 cut-off threshold. The wash buffers, scanner, and all
software are available from Agilent Technologies.
Mutation Screening by Capillary Sequencing
For ASD and schizophrenia cases and 130 controls, DNA was
extracted from lymphocytes and lymphoblastoid cell lines. Primers
flanking coding exons were designed with Primer3 (Table S III,
supplemental material). Genomic DNAwas PCR amplified in aMJ
Research DNA Engine Tetrad 2. The 15 ml final volume contained
40 ng DNA, 0.3mM each primer, 0.5U Qiagen HotStarTaq DNA
Polymerase, 1.5mM MgCl2, and 200mM each dNTP. The con-
ditions consisted of an initial incubation of 95C for15min, fol-
lowed by 30 cycles at 94C for 45 sec, 60C for 45 sec, and 72C for
60 sec. The final incubation step was at 72C for 7min. Aliquots of
5ml ofPCRamplifiedDNAfragmentswereprepared for sequencing
with Exonuclease I/Shrimp Alkaline Phosphatase digestion using
2ml of USBCorporation ExoSAP-IT for 30min at 37C followed by
enzyme deactivation at 80C for 15min. A 2ml aliquot of the
ExoSAP-IT treated PCR product was cycle sequenced with Applied
Biosystems BigDye Terminator v3.1 on aMJ ResearchDNAEngine
Tetrad 2. The conditions were, 10ml final volume, 1.5ml Big Dye,
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4 pmol primer, and 2ml of 5M Betaine, initial incubation of 96C
for 2min followed by 25 cycles at 95C for 15 sec, 50C for 10 sec,
and 60C for 4min. The dye labeled sequencing reaction products
were capillary electrophoresed on a Applied Biosystems 3130XL
Genetic Analyzer with a 36 cM array, 3130 POP-7 polymer, 3130XL
Data Collection v3.0 and Sequencing Analysis Software v5.3.1.
Further analysis was performed with SeqScape 2.1 or DNASTAR
Lasergene 8.1.
Mutation Screening by Next-Generation
Sequencing
Exome sequence data were produced by the University of
Washington Genome Sciences Genomic Resource Center using
the same methods for exome capture, massively parallel sequenc-
ing, readmapping, and annotation as previously described [Norton
et al., 2011]. Sequences were analyzed across the GNB1L gene
for coding exons 3–8 for 500 self-identified European-Americans
and 414 African-Americans.
Mutational Burden Analysis
In concordance with work on Mendelian disorders where rare
variants of large effects are causal, our assumption was that poten-
tially pathogenic GNB1L variants would be rare changes that are
evolutionary conserved and predicted to have deleterious effects on
protein function. To evaluate evolutionary conservation of discov-
ered variants we used PhastCons [Siepel et al., 2005] and GERP
[Goode et al., 2010], and to evaluate putative effects of amino
acid change on protein function we used Polyphen [Ramensky
et al., 2002], pMUT [Ferrer-Costa et al., 2005], and SIFT [Ng and
Henikoff, 2003]. To deem a variant potentially pathogenic, we
required it to be determined as evolutionarily conserved with
at least one of the two methods, and considered damaging with
at least two of the three methods.
RESULTS
Proband and Family
The proband was seen in the Genetic Medicine Clinic at the
University of Washington for deteriorating cognitive and social
functioning. He had a history of autism as a child, schizophrenia as
a teenager and a persistent, variably severe problem with speech
production. The perinatal period was marked by emergency cesar-
ean section at 29 weeks gestation, birth weight of 1,304 g, and
2 months hospitalization. Despite these complications, he met
developmental milestones, walked at approximately 1 year, and
spoke single and then combined words between 1 and 2 years.
However, in early childhood he had a tendency to memorize
phrases, paced in circles, and appeared to ‘‘imagine things.’’
In kindergarten he was found to have receptive and expressive
languagedelays that qualifiedhim for special education services and
school records indicate that in the first grade hewas evaluated at the
Child Development and Rehabilitation Center at Oregon Health
and Science University and diagnosed with autism. Cognitive
testing was performed on several occasions. Full scale Wechsler
Intelligence Scale for Children III (WISC-III) [Wechsler, 1992] IQ
scores of 76 and 87 were obtained at ages 6.2 and 7.6 years,
respectively. At 16.5 years performance tests from the Wechsler
Individual Achievement Test II (WIAT-II) [Wechsler, 2002]
demonstrated a wide range of scores, from 111 (77th percentile)
for phonological decoding to 40 (<0.1 percentile) for math
reasoning.
In the public school system he received special education
and speech services. The deterioration of expressive language
was noted, and he never spoke more than one or two words at a
time. In the 8th grade, he began acting confused, his behavior
became more erratic with episodes of anger and violence, and he
reported hearing voices and ‘‘beeping noises.’’ At age 14 he was
hospitalized with visual, olfactory hallucinations, and dysregulated
behavior and a diagnosis of schizophrenia was made. Although
his behavior stabilized on a combination of antipsychotic medi-
cations, he continued tobe intermittently agitated anddisorganized
and to complain of auditory hallucinations. In later teen years, he
became more anxious and was started on a selective serotonin
reuptake inhibitor. There is no history of seizures and no seizure
activity was detected on multiple EEGs. A recent brain MRI was
normal.
On examination by a medical geneticist and a child and adoles-
cent psychiatrist at the University of Washington at age 18 no
physical features of VCFS were detected. The neurologic exam was
normal. The patient was casually dressed and cooperative but
avoided eye contact, except when he was directly addressed. He
sat somewhat restlessly in the chair, with stereotypic movements
characterized by rubbing his hands back and forth over his knees. At
times, it appeared that he was gesticulating with his mouth as if
he were talking to someone. It appeared that he is struggling with
speech production. He would respond verbally to some questions,
but only after a long delay and with only one or two words, making
mental status examination difficult. It was notable that there was
no delay in his nonverbal responses. The clinical diagnosis by the
psychiatrist was pervasive developmental disorder not otherwise
specified and psychosis not otherwise specified. A structured
psychiatric evaluation was not performed and available records
were insufficient for establishment of a structured diagnosis.
Cytogenetic Evaluations
Karyotype analysis revealed a balanced translocation, t(1;22)-
(p36.1;q11.2) (Fig. 1). FISH was performed in the University of
Washington clinical laboratory with two probes for chromosome
22q. Signals for the 22q11.2 VCFS probe were observed on both
the normal and derivative chromosomes 22, while signals from the
distal 22q13.3 ARSA probe were observed on the normal chromo-
some 22 and derivative chromosome 1 (Fig. S1, supplementary
material). Additional cytogenetic evaluations revealed that the
proband’s father and several other paternally related family mem-
bers are balanced translocation carriers, which is consistent with
the history of infertility and multiple pregnancy losses. There
was no history of developmental disability, autism or psychosis
in these or other relatives, but neuropsychiatric testing was not
done. A pedigree is not shown because of concerns regarding
identifiability.
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Characterization of the Translocation
Breakpoints
CGH with somatic cell hybrids that each contained one derivative
chromosome was used to fine map the translocation break
points. To precisely determine the translocation location, primers
spanning the breakpoint were designed and the region was
sequenced. The chromosome 1 breakpoint is at 25,434,753 bp
(NCBI36/Hg18). (Fig. S2, supplementary material). The chromo-
some 22 breakpoint is at 18,167,843-18,167,854, encompassing a
10 bp deletion (tcttctctgc) (Fig. 2). The chromosome 1 breakpoint
lies in aheterochromatic regionofALUrepetitiveDNAbetween the
SYF2 andC1orf63genes. The chromosome22q11.21 breakpoint lies
within intron 7 of the GNB1L gene, a region without repetitive
DNA. No homology was found between the two breakpoints.
GNB1L has 8 exons spanning 66.5 kb of genomic DNA encoding
327 amino acids (NP_443730). The fusion predicts substitution of
16 amino acids from the noncoding ALU sequence of chromosome
1 in place of the terminal 83 amino acids of GNB1L. No other
abnormalities of sequence dosage for chromosomes 1 or 22 were
detected by whole genome CGH (data not shown).
FIG. 1. Karyotype showing the balanced translocation
t(1;22)(p36.1;q11.2) in the proband and other members of his
family. Arrows indicate derivative chromosomes 1 and 22.
FIG. 2. Fine mapping of the chromosome 22 translocation breakpoint. The derivative chromosome 22 was differentially labeled with Cy3-dCTP,
derivative chromosome 1was labeled with Cy5-dCTP and both were hybridized to chromosome 22 specific oligonucleotide array (NimbleGen HG 18
Chr22 design). The hybridization localized the breakpoint at sufficiently high resolution (A) to enable PCR based breakpoint cloning (B). The
chromosome22breakpoint is between18,167, 843-18, 167,854 bp,within intron7of theGNB1Lgene, andencompassesa10 bpdeletion shown in
lower case (tcttctctgc). [Color figure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/ajmgb]
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Copy Number Assays we detected
GNB1L duplications in two subjects with ASD. By array CGH we
determined that both are the typical 3Mb dup22q11.2.
We sequenced the 6 coding exons and splice junctions ofGNB1L
in genomic DNA of 271 subjects with schizophrenia and 513
subjects with ASD. In this sample we identified five missense
variants we define as rare as they are not listed in the NCBI dbSNP
Build 132 (R57Q, C70R, R88W, R283Q, andV290M). Two of these
variants R57Q and C70R, were detected in multiple controls of
European-American and African-American background and are
likely to be polymorphisms. The three private variants found in
ASD subjects, R88W, R283Q, and V290M, affect residues in the
WD40 domains and meet our criteria for missense variants that
are highly conserved across multiple species as determined by
PhastCons and GERP, and predicted to have pathogenic effects
on the protein structure by at least two of three software algorithms
(SIFT, PolyPhen, and pMUT). No rare variants were detected in
schizophrenia sample. For a control sample we have evaluated
coding sequence of 630 controls of European-American and 414
controls of African-American ancestry. In this combined sample
of 1,044 controls, we have identified four variants that were not
present in dbSNPBuild 132, none ofwhich havemet our criteria for
deleteriousness based on conservation score and effects on protein
function (Fisher Exact, two sided P¼ 0.036) (Table I). Figure 3A
shows the genomic organization ofGNB1L and the protein location
of unique variants identified in ASD cases.
Transmission in Families
The duplications identified in the probands were genotyped in all
available members of both families (Fig. 4). In family AU142, the
3Mb duplication was transmitted from the father to both affected
monozygotic twin daughters, one of whom had autism and the
other had a diagnosis of ASD. Both had low IQ scores (full-scale IQ
49). The father showed decreased social motivation and limited
range of interests/flexibility as assessed by the Broader Phenotype
Autism Symptom Scale (BPASS) [Dawson et al., 2007]. In family
M2017 the duplication is a de novo event in one of the two affected
offspring with a diagnosis of autism.
All three private missense variants were transmitted from an
unaffected parent (Fig. 3B). In family AU169, both affected sons
with autism and the unaffected daughter inherited the R88W
variant; the carrier father had elevated BPASS scores, indicating
presence of the broader autism phenotype. In families AU498 and
AU510, a brother with ASD did not carry the respective R283Q or
V290M variant. The carrier mother in family AU510 showed
subclinical traits of the autismphenotype as reflected by an elevated
BPASS score, as did the noncarrier father in family AU498.
DISCUSSION
There is increasing evidence that autism and schizophrenia are
highly heterogeneous disorders on both phenotypic and genotypic
levels [McClellan et al., 2007; Abrahams and Geschwind, 2008;
Bassett et al., 2010; State, 2010]. Recent molecular studies have
identified multiple risk factors for both disorders. For autism there
is evidence for a pathogenic effect of missense mutations in a
number of genes, including NLGN3 (MIM 300336) and NLGN4
(MIM 300427) [Jamain et al., 2003],NRXN1 (MIM 600565) [Kim
et al., 2008], SHANK3 (MIM 606230) [Durand et al., 2007],
SHANK2 (MIM 603290) [Berkel et al., 2010], and CNTNAP2
(MIM 604569) [Bakkaloglu et al., 2008]. In addition to the
22q11.2 region, recurrent deletions and duplications at 7q11.3,
15q11–q13, 16p11.2, and 17p11.2 have autism as a frequent phe-
notypic presentation [Cook and Scherer 2008; Stankiewicz and
Lupski, 2010). None of these single gene mutations or CNVs
account for more than a minority of autism cases. Similarly, for
schizophrenia, the list of candidate genes and CNVs continues to
increase [Bassett et al., 2010; Stankiewicz and Lupski, 2010].
TABLE I. Summary of Rare Missense Variants Detected in ASD Cases and Unscreened Controls



















ASD cases (n¼ 513)
c.262G/A p.R88W 18,179,963 1 Damaging Damaging Damaging 1 4.61
c.848C/T p.R283Q 18,156,368 1 Benign Damaging Damaging 1 0.938
c.868C/T p.V290M 18,156,348 1 Damaging Benign Damaging 0.997 4.97
Controls (n¼ 1,044)
c.17G/A p.P6L 18,188,862 1 Benign Benign Benign 0 4.38
c.313C/T p.V108M 18,179,903 1 Damaging Benign Benign 0.068 0.158
c.692G/A p.A231V 18,169,564 1 Benign Benign Benign 0.988 2.91
c.913G/A p.A305T 18,156,303 1 Benign Benign Benign 0 9.54
aPhastCons scores range from 0 to 1, where 1 is most conserved.
bGERP conservation scores range from 11.6 to 5.82, where 5.82 is most conserved.
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FIG. 3. Schematic of GNB1L and corresponding protein and transmission of GNB1L variants in families with autism. A: The chromosome 22
translocation breakpoint lies in intron 7. The locations of the three unique variants found in ASD in the WD40 motifs are indicated. B: Affected
individuals in all families have a diagnosis of autism or ASD, indicated by black fill. Up-arrow indicates an elevated BPASS social motivation and
range of interest/flexibility scores; scores have a direct correlation with symptoms of ASD such that high scores are abnormal.
FIG. 4. Identification of GNB1L duplication and transmission patterns in two families with autism. Affected individuals in the pedigrees have a
diagnosis of autism or ASD, indicated by black fill. Up-arrow indicates elevated BPASS socialmotivation and range of interest/flexibility scores. (þ)
indicates 22q11.2 duplication shown as increased copy number by TaqMan and CGH. [Color figure can be seen in the online version of this article,
available at http://wileyonlinelibrary.com/journal/ajmgb]
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To date, the cumulative results point to involvement ofmany genes
and unknown environmental influences on the pathogeneses of
autism and schizophrenia and the variability in their phenotypic
expression.
Althoughdeletionof the22q11.2 region is associatedwith autism
and is the most common identified cause of schizophrenia, it is not
known which gene or genes confer this risk. The disruption of
GNB1L by a balanced translocation in the del22q11.2 region in our
proband with ASD as a child and schizophrenia as a young adult
suggests that this gene might play a role in neurobehavioral
phenotypes. Williams et al. 2008 reported significant evidence
for a male specific association between schizophrenia and geno-
types at the GNB1L locus and replicated these findings in two
independent samples with a total of 1,408 cases and 2,746 controls.
Furthermore, they found a significant allelic association between
the variants of GNB1L and psychosis in males with del22q11.2. By
direct sequencing of theGNB1L coding exons, they did not identify
any novel variants, but this was a limited re-sequencing study of
only 14 subjects. The association of common GNB1L alleles and
schizophrenia was recently replicated in a Chinese sample [Li et al.,
2011].GNB1L (MIM 610778) encodes a 327 amino acid G-protein
beta-subunit-like polypeptide that belongs to theWD-motif repeat
protein family. GNB1L protein contains six putativeWD40 repeats
and no other recognizable functional domains [Gong et al., 2000].
WD-motif containing proteins have 4–16 repeating units, all of
which are thought to form a circularized beta-propeller structure.
Members of the WD-motif family are found in all eukaryotes
and are involved in a variety of cellular processes, including cell
cycle progression, signal transduction, apoptosis, and gene regula-
tion. WD-repeat proteins have been associated with inherited
neurodevelopmental and neurodegenerative diseases, such as
lissencephaly-1 (MIM 607432), Parkinson disease type 8 (MIM
607060), Cockayne syndrome type A (MIM 216400), Triple-A
syndrome (MIM 231550), microcephaly (MIM 600176), and Jou-
bert SyndromeType 3 (MIM608629). Inmice, Gnb1l is an essential
protein as homozygous loss of function causes embryonic lethality
[Paylor et al., 2006]. It is widely expressed in the forebrain,
midbrain, and hindbrain structures of the adult mouse, and hemi-
zygous deletion of Gnb1l is associated with deficits in prepulse
inhibition of the startle response, a schizophrenia endophenotype
[Braff et al., 2001].
All of these factors motivated our evaluation of the contribution
ofGNB1L variants to autismand schizophrenia.As largemultigenic
22q11.2 CNVs are responsible for del22q11.2 and dup22q11.2
genomic disorders, we first evaluated GNB1L for copy number
changesusingTaqManassays that could, inprinciple, detect smaller
single gene CNVs. In this fashion we have detected two GNB1L
duplications in ASD subjects that we confirmed with CGH as 3Mb
multigenic duplications. As is true for the del22q11.2 syndrome,
the newly recognized dup22q11.2 syndrome is characterized by
cognitive and behavioral disturbances and extensive phenotypic
variability [Ensenauer et al., 2003; Yobb et al., 2005; Mukaddes
and Herguner, 2007; Ou et al., 2008; Yu et al., 2008; Lo-Castro
et al., 2009]. In one of our families the dup22q11.2 was transmitted
from a parent who had elevated BPASS scores for social motivation
and range of interest/flexibility. The BPASS was developed for use
with child and adult relatives as well as affected children to assess
social motivation, social expressiveness, conversational skills, and
flexibility, domains that are abnormal inASD [Dawson et al., 2007].
The BPASS scores were designed to span the range from clinical
impairment to typical behavior and have a direct correlation with
symptoms of ASD such that high scores indicate abnormality or
impairment in autism related traits. Although the father had
normal cognition, his monozygotic twin daughters share low IQ
scores but differ with respect to severity of behavioral impairment.
In the second family one of the two autistic siblings has a de novo
duplication, suggesting that in this family additional risk factors are
present. We are not aware of any publication that has found an
associationof dup22q11.2with schizophrenia andwedidnotdetect
either deletion or duplication of 22q11 in our relatively small
sample of 271 schizophrenic subjects. It is interesting to note
that the del22q11.2 is associated with schizophrenia and autism
and dup22q11.2 has been described only in autism, suggesting
shared genetic influences modulated by gene dosage.
Our second assumption was that rare coding sequence changes
in GNB1L might be responsible for the phenotype in a subset of
ASD or schizophrenia cases. In 513 subjects with ASD we found
three rare missense GNB1L variants that affect highly conserved
nucleotides and are predicted to be deleterious. We have found no
such variants in a smaller sample of 271 schizophrenia cases. For
mutational burden analysis we defined potentially pathogenic
variants as not present in dbSNP, conserved and as having delete-
rious effects on protein function as determined by two out of three
bioinformatic functional prediction tools. Our assumption is that
variants defined in such a way that includes nucleotide-sequence
conservation and protein based prediction of functional effects are
likely to be deleterious regardless of the ethnic background of
subjects. The three ASD variants met those criteria and no variants
meeting these criteria were detected in 1,044 controls (P¼ 0.036).
The unique GNB1L variants in our families with autism were all
inherited. As with dup22q11.2, the variants did not co-segregate
with ASD diagnoses, suggesting the presence of additional risk
factors. In autism males outnumber females by approximately
fourfold, possibly a consequence of a lower threshold for expression
of the ASD phenotype in males. This hypothesis is consistent with
the transmission patterns we have observed. In the three autism
families with missense mutations four of the five males who carry a
variant have autism or ASD and the fifth has an elevated BPASS
score. In contrast, only one of three female carriers has an
elevated BPASS score. Our findings are consistent with the
hypothesis that GNB1L mutations are risk factors in a multigenic
threshold model for autism. Given the decreased penetrance and
marked variability in expression for the behavioral phenotypes
observed with deletion and duplication of the 22q11.2 region, it is
likely that any causal gene in the region would have decreased
penetrance as well. Decreased penetrance and variable phenotypic
expression have been observed for other genes in which rare
variants are reported to be associated with autism [Abrahams
and Geschwind, 2008; State, 2010] such as SHANK3 [Moessner
et al., 2007],NRXN1 [Kimet al., 2008], andCNTNAP2 [Bakkaloglu
et al., 2008].
Our study has several weaknesses. Although the 46,XY,t(1;22)-
(p36.1;q11.2) translocation disrupts the GNB1L gene, it is possible
that the resulting phenotype is due to position effects that alter
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expression of genes in the vicinity including TBX1 and COMT
which are also strong candidates for behavioral phenotypes. In our
screening ofGNB1L for potentially damaging sequence variants we
found an association of rare potentially damaging nonsynonimous
variants and ASD. This conclusion is based on the assumption that
currently available bioinformatic tools can accurately distinguish
variations that will change the protein function and ultimately
result in a behavioral phenotype. An additional weakness is that our
cases and controls contain several ethnic and racial groups and their
ethnic classification is based on self-identification. It is possible that
the variants we have identified as potentially deleterious are poly-
morphisms in one of the ethnic subpopulations. Our findings
should be replicated, preferably in a larger sample of cases, as it
is likely that the contribution of rare variants in any one gene is
responsible for a very small proportion of the genetic burden for
complex disorder such as autism.
If our finding that rare missense GNB1L variants contribute to
ASD in a subset of cases is replicated, studies would be warranted to
determine the effects of such mutations on the GNB1L protein
whose function is not well understood. AsGNB1L lies in the critical
del22q11.2 region it is a priori a candidate gene for neurodeve-
lopmental disorders that occur in the associated CNV syndromes.
Coupled with observations of other investigators for its involve-
ment in schizophrenia, our detection of a translocation disrupting
GNB1L and potentially damaging, extremely rare GNB1L variants
in subjects with autism provides evidence that this genemay have a
role in the pathogenesis of autism and expands the number of
phenotypes associated with GNB1L.
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